BCG Unresponsive Disease

BOND-003 With Dr. Mark D. Tyson: Cretostimogene for BCG-Unresponsive Bladder CancerПодробнее

Clinical Investigations in the Treatment of Urothelial CarcinomaПодробнее

Frontline vs Sequenced Therapies in BCG-Unresponsive Bladder Cancer: What's the Best Approach?Подробнее

Dr Li on Cretostimogene Grenadenorepvec Plus Pembrolizumab in BCG-Unresponsive NMIBCПодробнее

KEYNOTE-057: Outcomes for Patients With BCG-Unresponsive NMIBC Who Do Not Respond to PembrolizumabПодробнее

Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC With CIS #bladdercancer #cancer #newsПодробнее

Non-Muscle-Invasive Bladder Cancer Management Post-BCG Therapy | BackTable Urology ClipsПодробнее

AUA2024: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common ProblemsПодробнее

Treatment Options for BCG-Unresponsive NMIBC: Balancing Efficacy, Logistics, and Patient PreferencesПодробнее

Global Advancements in Bladder CancerПодробнее

BCG-Unresponsive Bladder Cancer: Rechallenging With Rescue BCGПодробнее

SPOTLIGHT video | Phase 2 trial of atezolizomab in BCG unresponsive bladder cancerПодробнее

Nadofaragene Firadenovec for BCG-Unresponsive NMIBC: 5-Year Follow-UpПодробнее

High-risk, BCG-unresponsive NMIBC beyond RC: intravesical and systemic therapiesПодробнее

Final Results of CORE-001: Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC With CISПодробнее

Innovations in treatment options for patients with BCG-unresponsive urothelial carcinomaПодробнее

Investigating novel treatment options for BCG-unresponsive urothelial carcinomaПодробнее

Urinary MRD Detection for Predicting Recurrence, Response to Nadofaragene in BCG-Unresponsive NMIBCПодробнее

Why do BCG-unresponsive patients with NMIBC refuse radical cystectomy?Подробнее

Real-world evaluation of nadofaragene firadenovec in BCG-Unresponsive NMIBCПодробнее